Corpus Intelligence IC Memo — BRANDYWINE HOSPITAL 2026-04-26 09:35 UTC
IC Memo — BRANDYWINE HOSPITAL
Investment Committee Memorandum | PA | 155 beds | Grade D | EBITDA uplift $2.8M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

BRANDYWINE HOSPITAL

CCN 390076 | CHESTER, PA | 155 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

BRANDYWINE HOSPITAL is a 155-bed under-performing / distressed in CHESTER, PA with $38.4M in net patient revenue and a -69.0% operating margin. The hospital serves a payer mix of 27.3% Medicare, 4.0% Medicaid, and 68.7% commercial.

Thesis: Undervalued. Our ML models identify $2.8M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -69.0% to -61.7% (+736bps).

Net Revenue HCRIS$38.4M
Current EBITDA COMPUTED$-26.5M
Operating Margin COMPUTED-69.0%
Occupancy HCRIS45.3%
Revenue / Bed COMPUTED$248K
Net-to-Gross HCRIS14.7%
Distress Probability ML49.1%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
101
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -69.0% places it below the state median. Among 101 size-comparable peers (78-310 beds), the median margin is -7.5%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (78-310), prioritizing same-state peers. 101 hospitals in the comp set.

HospitalStateBedsRevenueMargin
BRANDYWINE HOSPITAL (Target)PA155$38.4M-69.0%
GEISINGER WYOMING VALLEY MED CPA309$782.7M5.9%
WESTERN PENNSYLVANIA HOSPITALPA255$776.4M11.1%
COMMUNITY MEDICAL CENTERPA266$474.1M3.1%
THE CHESTER COUNTY HOSPITALPA299$473.6M-8.9%
ROBERT PACKER HOSPITALPA252$471.8M-2.1%
WILLIAMSPORT HOSPITAL & MEDICAPA227$459.8M-8.4%
CROZER CHESTER MEDICAL CENTERPA296$459.6M-19.6%
MOUNT NITTANY MEDICAL CENTERPA248$441.7M12.6%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.8M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$807K+210bp18mo
Cost to Collect4.5%2.5%$769K+200bp12mo
Denial Rate Reduction12.0%6.5%$761K+198bp12mo
A/R Days Reduction5200.0%3800.0%$468K+122bp9mo
Clean Claim Rate88.0%96.0%$25K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$807K
Cost to Collect
$769K
Denial Rate Reduction
$761K
A/R Days Reduction
$468K
Clean Claim Rate
$25K
Total EBITDA Uplift$2.8M
Current EBITDA$-26.5M
+ RCM Uplift+$2.8M
Pro Forma EBITDA$-23.7M
Current Margin-69.0%
Pro Forma Margin-61.7%
WC Released (1x)$1.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-40.8M$-146.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-40.8M$-174.7M0.00x-100.0%
Bull Case9.0x11.0x$-36.8M$-178.7M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-36.8M$-205.7M0.00x-100.0%
Bear Case11.0x10.0x$-44.9M$-147.7M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-44.9M$-177.0M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
LowLow net-to-gross ratioLarge contractual allowances suggest pricing discipline issues. Mitigant: payer renegotiation is an additional upside lever

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 101 hospitals with 78-310 beds
  • Same-state prioritization (n=102)
  • Comp margins: P25=-18.2% / P50=-7.5% / P75=3.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.